Global Equitable AI Healthcare: Grant Initiatives and Innovations

By Crystal Lubbe

October 24, 2024

The South African Medical Research Council (SAMRC) site discusses the significant initiative “Grand Challenges: Catalysing Equitable AI Use for Improved Global Health.” Overall, this program focuses on leveraging artificial intelligence (AI) to enhance healthcare systems worldwide.

Funding and Grants for Equitable AI

The Grand Challenges (GC) Network, including partners, Bill & Melinda Gates Foundation and Grand Challenges from Africa, Brazil, Ethiopia, India, and Senegal, has announced grants to support over 50 researchers and innovators. Notably, these grants form part of the initiative addressing global health challenges with Equitable AI Healthcare solutions.

Focus Areas of Equitable AI Healthcare

Funded projects under the Grand Challenges program focus on several critical healthcare areas, including:

  • Clinical Decision Support
  • Population Health & Policymaking
  • Support for Frontline Health Workers
  • Health Communications & Patient Journeys
  • Health Systems Strengthening
  • Clinical trials
  • Diagnostics
  • Population health.

Equitable AI Use

The initiative stresses the importance of an equitable approach to AI use, particularly in low- and middle-income countries (LMICs). Moreover, it seeks to ensure that the benefits of AI are relevant, affordable, and accessible, especially in communities where global health challenges are most pressing. By promoting equitable AI use, the program aims to enhance health outcomes for underserved populations.

Global Collaboration

This program is the product of collaborative efforts among various partners, including the SAMRC, the Bill & Melinda Gates Foundation, and other Grand Challenges supporters. Therefore, this cooperation emphasises the significance of local innovation paired with global backing to develop effective AI solutions tailored to specific regions.

Impact and Vision

The initiative accordingly hopes to transform healthcare delivery and improve countless lives globally. It aligns with the GC Network’s overarching vision of fostering local, regional, and global innovation ecosystems that address health and development issues with an emphasis on equitable AI use.

Funding Scale

The GC Network has invested greatly in innovative solutions, with over $1.6 billion awarded in 3,800 grants across 118 countries. The ongoing funding call reflects the commitment of the Grand Challenges initiative to support health and development innovation.

Quotes and Endorsements

Professor Ntobeko Ntusi (SAMRC) and Trevor Mundel (Gates Foundation), have expressed their robust support for the initiative. Furthermore, they emphasise the potential of equitable AI use to significantly enhance health and well-being on a global scale.

In conclusion, this initiative not only showcases a commitment to leveraging AI for global health improvement but also emphasises the importance of equity, local innovation, and collaborative efforts. With the focus on equitable AI use at its core, the Grand Challenges program stands poised to make a substantial impact in addressing urgent global health needs.

Reference url

Recent Posts

Strategic Avalere Health Appointments Enhance Leadership in Navigating US Healthcare Policy Changes

By João L. Carapinha

December 17, 2025

Avalere Health strengthened its appointments, with Matt Kazan returning as Senior Vice President of Policy, where he previously served as a former top advisor on the US Senate Committee on Finance, and he will now lead the policy team amid changes like the Inflation Reduction Act. Laura Housman, ...
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
BIC/LEN HIV Regimen Delivers Non-Inferior Results in ARTISTRY-2 Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial, demonstrating that the investigational BIC LEN HIV regimen
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggressive Prostate Cancer

By HEOR Staff Writer

December 16, 2025

AKEEGA BRCA2 Approval Ushers in Precision Era for mCSPC The AKEEGA BRCA2 approval by the U.S. Food and Drug Administration (FDA) on December 12, 2025, represents a breakthrough for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). Johnson & Johnson...